Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

It is now apparent that nearly every Trump appointee is a diehard anti-China high priest or priestess. That’s not just Marco ...

The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...

Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

Innophore will launch the CavitOmiX AI tool to screen for new drugs, predict side effects, and repurpose existing molecules.

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

A Chinese pharmaceutical company expects to hire up to 500 employees for the first phase of its new campus in northern ...

Find insight on Tencent, TikTok, Reach and more in the latest Market Talks covering Technology, Media and Telecom.

Shares of WuXi group companies jumped Monday after U.S. President-elect Trump promised to save TikTok and held a call with his counterpart in China, sparking tentative hopes that some areas of ...

NEW DELHI: India is bracing for possible disruptions to its pharmaceutical industry - where the American market accounts for ...